ro7

RO7185876 is a selective gamma secretase modulator, which can be used in the study of Alzheimer's disease.

RO7122290 is a bispecific antibody-like fusion protein composed of a trimeric ligand for the T-cell co-stimulatory receptor 4-1BB (CD137) and an antigen-binding fragment (Fab) targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulatory and antitumor activities. It shows promise in the treatment of advanced solid tumors. Molecular weight: 177.78 KD.

RO7196472 is a potent macrocyclic peptide antibiotic that selectively inhibits the activity of Acinetobacter strains. It targets the lipopolysaccharide (LPS) binding site on the inner membrane's LptB2FG complex, inhibiting lipopolysaccharide transport and thereby suppressing the activity of Acinetobacter strains.

(9R)-RO7185876 (Compound example 16) is a γ-secretase inhibitor. It reduces the secretion of Αβ42. This compound can be employed in the research of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, multi-infarct dementia, senile dementia, or Down syndrome.

RO-7 is a next-generation polymerase (PA) endonuclease inhibitor of influenza A and B viruses.

RO 7-0213 is a novel benzodiazepine (RO7-0213) containing a fully positive quaternary ammonium component.

Ro 7-9767 is a biochemical.